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Abstract. Treatment recommendations within Clinical Practice Guide-
lines (CPGs) are largely based on findings from clinical trials and case
studies, referred to here as research studies, that are often based on
highly selective clinical populations, referred to here as study cohorts.
When medical practitioners apply CPG recommendations, they need to
understand how well their patient population matches the characteristics
of those in the study cohort, and thus are confronted with the challenges
of locating the study cohort information and making an analytic com-
parison. To address these challenges, we develop an ontology-enabled
prototype system, which exposes the population descriptions in research
studies in a declarative manner, with the ultimate goal of allowing medi-
cal practitioners to better understand the applicability and generalizabil-
ity of treatment recommendations. We build a Study Cohort Ontology
(SCO) to encode the vocabulary of study population descriptions, that
are often reported in the first table in the published work, thus they are
often referred to as Table 1. We leverage the well-used Semanticscience
Integrated Ontology (SIO) for defining property associations between
classes. Further, we model the key components of Table 1s, i.e., collec-
tions of study subjects, subject characteristics, and statistical measures
in RDF knowledge graphs. We design scenarios for medical practitioners
to perform population analysis, and generate cohort similarity visualiza-
tions to determine the applicability of a study population to the clinical
population of interest. Our semantic approach to make study popula-
tions visible, by standardized representations of Table 1s, allows users to
quickly derive clinically relevant inferences about study populations.
ResourceWebsite: https://tetherless-world.github.io/study-cohort-ontology/
Keywords: Scientific Study Data Analysis · Knowledge Graphs · Mod-
eling Aggregations and Summary Statistics · Ontology Development
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1 Introduction
Our goal is to build a semantic solution to model the descriptions of study pop-
ulations and to assist medical practitioners in determining the applicability of a
study to their clinical population. Through Fig. 1, we describe the components
of a prototype system, that utilizes knowledge representation (KR) techniques to
model tabular representations of study population descriptions, often captured
in the first table of the scientific publication. We build a Study Cohort Ontology
(SCO) (section 4) to support the vocabulary in these Table 1s (plural form) and
to model their structure. Further, we encode Table 1s as Resource Description
Framework (RDF) knowledge graphs (KGs) [3] (section 5) to expose in a declar-
ative manner3 these study populations. We demonstrate our ontology and the
use of our knowledge graphs with two applications (section 6): one aimed at
helping medical practitioners determine the similarity of a patient or a clinical
population to the study population, and another aimed at supporting retrospec-
tive analysis of a study to expose possible biases or population gaps, such as
racial underrepresentations.
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Fig. 1. An overview of the cohort analytics workflow which 1) ingests terms from
population descriptions of research studies, 2) standardizes their representations via
KR techniques and 3) supports study applicability applications. The numbering is
in-line with the figure and is indicative of data flow.
3 declarative manner: in a clear, unambiguous, and computer understandable manner
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1.1 Use Case
Evidence-based Medicine (EBM) has been gaining popularity, and medical prac-
titioners are using it more often. However, it is challenging to design the CPGs
to stay current with the growing body of clinical literature. Additionally, medical
literature is continuously being revised, e.g., typically, new versions of CPGs are
released annually. Treatment recommendations in CPGs are often supported by
evidence from cited research studies, i.e. clinical trials and observational case
studies, targeting highly selective populations with sociodemographic and co-
morbid characteristics. In clinical practice, it is well-known that there are biases
in clinical evidence that reduce their generalizability. The widely-cited research
article, “Trustworthy Clinical Practice Guidelines: Challenges and Potential,” [8]
states some of the problems in existing guideline practices, such as “Failure to
include major population subgroups in the evidence base thwarts our ability to
develop clinically relevant, valid guidelines.”
Furthermore, when medical practitioners are faced with the treatment of com-
plicated patients who do not wholly align with guideline recommendations, they
may want to consult research studies with relevant findings to determine if the
study applies to their clinical population. Hence, we are developing a semantic
solution to address these challenges, by providing medical practitioners access to
high-quality and applicable guideline evidence. We evaluate our solution on the
American Diabetes Association’s (ADA) Standards of Medical Care 2018 CPG
4 cited research studies, which we will introduce in section 3.
2 Related Work
Existing ontologies for study design and clinical trials are more focused on the
study design and methodology aspects of clinical trials, and their vocabulary
is insufficient to support cohort descriptions. ProvCaRe [22], an “Ontology for
provenance + healthcare research,” was developed to assess the scientific rigor
and reproducibility of scientific literature. Based on the NIH “Rigor and Repro-
ducibility” guidelines [13],this ontology identifies three components of a study
contributing to provenance: study methods (study protocol followed), study in-
struments (equipment and software used in the study),and study data (meta-
data about data collection). However, within the ProvCaRe ontology, support
for study data is limited to that of inclusion and exclusion criteria, and there
is no support for Table 1 terminology, such as subject characteristics and study
arms. The Ontology of Clinical Research (OCRE) [20], a widely cited study de-
sign ontology used to model the study lifecycle, addresses goals similar to our
study applicability scenario. They adopt an Eligibility Rule Grammar and On-
tology (ERGO) [21] annotation approach for modeling study eligibility criteria
to enable matching a study’s phenotype against patient data.
Since we encode a provenance component of guideline evidence, we searched for
4 ADA 2018 CPG at: https://diabetesed.net/wp-content/uploads/2017/12/
2018-ADA-Standards-of-Care.pdf
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ontologies for scientific publications. We found that most clinical trial ontolo-
gies, e.g., CTO-NDD [24], are domain specific and not directly reusable for a
population modeling scenario. Other ontologies, such as the EPOCH suite of
clinical trial ontologies [19], that was developed to track patients through their
clinical trial visits, had class hierarchies that were insufficient to represent the
types of publications cited in the ADA Standards of Care CPG. Additionally,
there is another cohort ontology [11] being developed. However, our modeling of
the association of descriptive statistics with subject characteristics differs from
their modeling decision to define new properties to represent these associations.
Instead, we introduce classes to accommodate new subject characteristic terms
upon Table 1 ingestion, and we limit the number of descriptive statistics to a
standard set of central tendency measures and boundary values. Hence, we do
not leverage their ontology. Further, their ontology is domain specific, includ-
ing many sleep disorder classes. In SCO we provide a generalized and richer,
domain-agnostic Table 1 vocabulary (sufficient to support research studies tar-
geting various diseases).
Clinical trial matching has been attempted multiple times, largely as a Natural
Language Processing problem, including a KR approach that improves the qual-
ity of the cohort selection process for clinical trials [17]. Clinical trial matching
work [17] was carried out with the help of an ontology, and TBOX (knowledge-
based) assertions were created from SNOMED-CT for supporting ABOX (real-
world) assertions of patient records. However, the focus of their effort was mainly
on efficient KR of patient data, and study eligibility criteria was formulated as
SPARQL queries on the patient schema. We tackle the converse problem of iden-
tifying studies that are applicable to a clinical population based on the study
populations reported. We address this problem from the perspective of modeling
the study populations.
3 Dataset
Our evaluation dataset is comprised of research studies, cited in the ADA Stan-
dards of Medical Care 2018 CPG. We manually reviewed the entire guideline
to understand the types of evidence utilized to support treatment recommenda-
tions. ADA treatment recommendations are supported through citations within
the discussion, which serve as implicit evidence for the recommendation. Fur-
ther, we used PubMed APIs5 on the Medline6 publications, cited in evidence
sentences across chapters of the ADA CPG, to retain only those publications
that met the qualifications for our definition of research studies. We only con-
sidered publications tagged with Pubmed Publication types7 of: Randomized
Controlled Trial, Clinical Trial, and Multicenter Study.
We focused on the pharmaceutical treatments and comorbidities associated with
type-2 diabetes, and we filtered our evaluation dataset to contain cited research
5 https://pypi.org/project/pubmed-lookup/
6 https://www.nlm.nih.gov/bsd/medline.html
7 Find the list of all supported publication types at https://www.ncbi.nlm.nih.gov/
books/NBK3827/table/pubmedhelp.T.publication_types/
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studies from the Pharmacologic Interventions (Chapter 8) [1] and the Cardiovas-
cular Complications (Chapter 9) [2] of the ADA 2018 CPG. We did a thorough,
manual investigation of research studies from these chapters, looking for any
variance in Table 1s and identifying important study data that explained Ta-
ble 1 variables. Furthermore, although we were able to gather full-text links
for Medline citations through programmatic means, we had to manually follow
these links to ensure they are freely available, and, if not, we checked for the
availability of the study in other sources. Due to these challenges, we narrowed
down the number of research studies to 20 that we list on our resources website.
4 Study Cohort Ontology
As introduced in section 1, we build a Study Cohort Ontology (SCO) to serve as
a vocabulary to model the components of a Table 1, the study arms (columns)
and their characteristics (rows). We also ensure that the implicit associations
exhibited between these components are reflected in SCO. We adopt a bottom-up
approach to modeling, that follows, as a by-product of our investigative efforts,
the description in section 3. Further, we have attempted to keep our main SCO
ontology as domain-agnostic as possible to ensure easy reuse and longevity. In
subsection 4.1, we introduce the main concepts in our ontology to provide a
contextual understanding of the descriptions of populations reported in Table
1s, and walk through our approach to ontology reuse in subsection 4.2.
4.1 Primary Classes and Property Associations
The descriptions of study populations that are reported in Table 1s follow a
pattern in which columns represent study arms, a group of study subjects who
receive an intervention or control regime. The subject characteristics are pre-
sented in rows, and are aggregated upon and reported via descriptive statistical
measures in the cells of the table. In a conceptual model of SCO as shown in
Fig. 2, we depict our modeling of these Table 1 components and the additional
details that are necessary to describe a study population in the context of a
research study. A more detailed version can be found on our resources website.
As will become evident from a representative Table 1 example shown in Fig. 3,
the row and column headers in Table 1s contain specific medical codes and vari-
ables that can further be grouped into broad general classifications: Anthropo-
metric Properties (chear:Anthropometry),8 Demographics (chear:Demographic),
8 We use the ontology prefixes: (1) sio: SemanticScience Integrated Ontology (2)
uo: The Units of Measurement Ontology (3) chear: Children’s Health Exposure
Analysis Resource Ontology (4) ncit: National Cancer Institute Thesaurus (5) prov-
care: ProveCaRe (6) doid: Human Disease Ontology (7) sco: Study Cohort Ontology
(8) hasco: Human-Aware Science Ontology (9) prov: The PROV ontology (10) dct:
Dublin Core Terms (11) vann: A vocabulary for annotating vocabulary descriptions
6 S. Chari et al.
Fig. 2. A) A high-level overview of SCO that captures the vocabulary and associations
needed to model the descriptions of study populations. B) We depict associations that
cannot be realized without actual instantiation of Table 1 data.
Laboratory Results (ncit:C36292), Diseases (doid:0004), and Medical Interven-
tions (provcare:Intervention). Further, we associate all these broad, general clas-
sifications we just identified, such as subject characteristics, diseases, interven-
tions etc., via sio:hasAttribute and sio:hasProperty relations to the study sub-
ject. More specifically, for properties such as disease and interventions that per-
sist over time and are characterized by the state the study subject exhibits,9 we
use a sub-property of sio:hasAttribute, i.e. sio:hasProperty, to link them to the
study subject. Additionally, we do not maintain certain property associations
(e.g. compositional relation between the study arm and study subject) in our
ontology and only create them upon the representation of actual Table 1 content
in RDF KGs. For the ease of understanding, we depict instances in pink in Fig.
2 to help visualize the realism in our modeling.
To summarize, essentially through SCO, we build a framework to model a set of
study subjects, who participate (sio:isParticipantIn) in a research study and be-
long to a study arm and whose subject characteristics are measured (sio:hasUnit)
in units, and are aggregated upon via descriptive statistics. Since we are dealing
with the biomedical domain, where multiple definitions may exist for a term,
through blank nodes and reification techniques we allow support for this and we
9 View the definition of sio:hasProperty and sio:hasAttribute relations at:
https://raw.githubusercontent.com/micheldumontier/semanticscience/master/
ontology/sio/release/sio-subset-labels.owl
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maintain provenance for our definitions via prov:wasAttributedTo (person) and
dct:source (online source). For example; hasco:ResearchStudy sio:hasAttribute [
a skos:definition; sio:hasValue ’A scientific investigation that involves testing a
hypothesis’; prov:wasAttributedTo AmarDas]. Additionally, we also provide ex-
ample usages of our terms via vann:example, to help future users/contributors
of our ontology get an idea of the intended usage of the class. Our main SCO on-
tology, and our accompanying suite of ontologies, Lab Results, Diseases, Drugs,
and Therapies, in which we maintain diabetes specific content, are available as
resources. Further, we tested our ontology with the Hermit reasoner.
4.2 Ontology Reuse
We reuse classes and properties from existing biomedical ontologies as much as
possible, and only define them ourselves when they do not exist. We primarily
reused ontologies available from Bioportal [16] that are regularly maintained and
have significant reuse. We have tried to reuse terms from a small set of appli-
cable ontologies to avoid enlarging the ontology when we bring in new classes
and additional axioms. We categorize the ontologies, from which we reuse terms,
broadly into Study Design ontologies (ProvCaRe, HASCO), Mid-Level ontolo-
gies (SIO), Medical ontologies (NCIT, CHEAR, etc.), and Statistical ontologies
(STATO, UO). We present a list of our reused ontologies against their groupings
on our resources website.
In our approach to ontology reuse, we include minimum information to refer-
ence a term (MIREOT) [5] for most of our reused ontologies, such as ProvCare
and NCIT, unless we leverage their structure completely. However, we do im-
port a light-weight version of the Child Health Exposure Analysis and Resource
(CHEAR) ontology, by applying the MIREOT technique to extract the demo-
graphics and anthropometric branches alone. We prefer to import the CHEAR
ontology, as it builds off SIO and additionally imports the HAScO human aware
science ontology, that we leverage. We utilized an online tool, Ontofox [23], to
apply the MIREOT technique to a few ontologies that were supported on this
platform. However, for ontologies that were not available on Ontofox, we de-
signed our own SPARQL query to gather subclass and superclass trees for a
given ontology class. On our resources website, we make our MIREOT Python
script available. This runs the SPARQL query against a Blazegraph endpoint
and returns the RDF version of the subset class tree.
5 Knowledge Graph Modeling
We use an annotated example of a Table 1, seen in Fig. 3, to explain our approach
of modeling the collections of study subjects, subject characteristics defined on
collections, and the descriptive statistics used to summarize these characteris-
tics. We present an RDF snippet in Listing 1.1, and explain smaller sub-portions
of our modeling in each subsequent subsection. These snippets form the funda-
mental pieces of our Table 1 KG. On our resources website, we release the KG
8 S. Chari et al.
representations of the studies in our evaluation dataset, for interested readers to
run their analyses.
Fig. 3. An annotated example of Table 1 from a clinical trial “Telmisartan, ramipril,
or both in patients at high risk for vascular events” [10] cited in the Cardiovascular
Complications (Chapter 9) of the ADA CPG
.
5.1 Modeling of Collections of Study Subjects
Listing 1.1. Representation of a portion of the Ramipril Study Arm
sco-i:RamiprilArm
a owl:Class, sco:InterventionArm;
rdfs:subClassOf sio:StudySubject;
sio:isParticipantIn sco-i:TelmisartanRamiprilStudy;
sio:hasAttribute
[ a sco:PopulationSize; sio:hasValue 8576],
[ a sio:Age; sio:hasUnit sio:Year;
sio:hasAttribute
[ a sio:Mean; sio:hasValue 66.4],
[a sio:StandardDeviation; sio:hasValue 7.2 ]
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] .
Study arms are specific subpopulations of study cohorts comprised of a subset
of enrolled study subjects. Hence, they are a natural fit for modeling as classes
in the OWL web ontology language [4], “Classes provide an abstraction mecha-
nism for grouping resources with similar characteristics. Like RDF classes, every
OWL class is associated with a set of individuals, called the class extension.”,
and model collections as classes.
As discussed earlier in subsection 4.1, study arms are represented as columns
in Table 1s. Further, the RDF snippet in Listing 1.1 shows a semantic defini-
tion of a particular study arm as an instance of the sco:InterventionArm. Study
arm definitions are either those of InterventionArm or ControlArm and they are
gathered from the Table 1 columns themselves, if sufficient, if not we consult the
study data to find relevant content that describes the arms.
In some Table 1s, there also exist subsets of study arms, created by the presence
of categorical row variables (e.g. percentage of Asians), expressed in percent-
ages10. Such subsets are expressed as rdfs:subClassOf the main study arm, and
have an owl:Restriction defined on them for membership. An example of the
representations of these subsets, can be viewed as a part of the KG creation
documentation on our resources website.
5.2 Modeling of Characteristics and Descriptive Statistics
As briefly introduced in subsection 4.1, subject characteristics are the phenotype
properties that are collected for study subjects. In our evaluation dataset, we
have observed that all study arms belonging to a study share the same set
of characteristics. However, the range of values for these characteristics differ
across study arms depending on their composition. Borrowing from our grouping
of characteristics from section 4, we reemphasize that characteristics persisting
over a period of time are modeled as sio:hasProperty, and the rest are modeled
via sio:hasAttribute property. From this discussion it becomes apparent that our
modeling of characteristics on study arms is fairly straightforward and we only
utilize two SIO property associations. In Listing 1.1, we depict the association of
age as a sio:hasAttribute of the Ramipril study arm. Further, characteristics can
also be classified broadly as categorical, discreet, and continuous. Categorical
characteristics are represented in subsets, and their representation is discussed
in the previous subsection.
5.3 Modeling of Descriptive Statistics
Another problem we address in this paper is the KR of aggregate statistics on
subject characteristics of study populations. Although aggregate statistics are
reported in multiple domains, there has been little work on a convention for
10 More Table 1 reporting style and composition details at https://prsinfo.clinicaltrials.
gov/webinars/module6/resources/BaselineCharacteristics_Handouts.pdf
10 S. Chari et al.
supporting the modeling of aggregations in RDF. The support for aggregations
in Linked Data is presented in [6]. However, their process is more focused on
the publishing of statistical data and the metadata than on the representation
of statistical data itself.
Descriptive statistics have conventionally been defined, as statistical measures
that summarize the data.11 In Table 1s, they are used to describe summarized
values of the characteristics of study subjects, who belong to a study arm. From
our analysis of Table 1s, we have seen a limited set of descriptive statistics
measures: mean +/- standard deviation, median +/- interquartile range, and
percentages. We model these aggregations and descriptive statistics, seen as rei-
fied triples on a property. Reification is an RDF technique developed to “make
statements about statements” [18]. As can be seen in the RDF snippet above, we
define descriptive statistics as reified triples on an age characteristic. Addition-
ally, since we only reuse SIO object and data properties, we eliminate the need
for further punning techniques, to represent these descriptive statistic properties
as instances of sio:hasAttribute. In this paper, we only present an example of
a mean +/- standard deviation measure. Examples of representing median +/-
interquartile via sio:MinimalValue and sio:MaximalValue boundary classes, and
percentage association, can be viewed on our resources website.
6 Applications
Our study applicability applications leverage the declarative specifications of
study populations in our Table 1 KG. In subsection 6.1, we frame three scenarios
of clinical relevance that mimic the decision-making of a medical practitioner
to determine study applicability. Additionally, we present a cohort similarity
visualization strategy in subsection 6.2. In subsection 6.3, we describe a faceted
browser interactive visualization tool aimed at medical practitioners. Moreover,
as shown in Fig. 1, we include study details in our application results. Hence,
we provide medical practitioners with provenance-justified results that could be
used for future analyses and investigation.
6.1 Population Analysis Scenarios
As discussed in section 1.1, there exist challenges with study biases and the
varying quality in research studies. Medical practitioners need to be aware of
these issues when deciding on applicable studies for their clinical population.
Three scenarios of clinical relevance were suggested by our medical expert on the
Health Empowerment by Analytics, Learning and Semantics (HEALS) project.
Through queries to our Table 1 KG we address a representative competency
question for each of these scenarios: (1) Study match: Is there a study that
matches this patient on a feature(s)? (2) Study limitation: Is there an absence
or an underrepresentation of population groups in this study? (3) Study quality
11 Definition adapted from: https://en.wikipedia.org/wiki/Descriptive_statistics
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Fig. 4. A snapshot of our faceted browser tool that provides medical practitioners with
the ability to customize cohort analyses. Currently, the feature facets are limited to
the patient features from NHANES, that overlap with, Table 1 data. If a study doesn’t
contain some of these 5 features, they will be disabled.
evaluation: Are there adequate population sizes and is there a heterogeneity
of treatment effects among arms? Our declarative representations of Table 1s,
allow us to trigger retrospective queries that combine subject characteristics
(SPARQL AND clauses), various descriptive statistical representations (limited
patterns of modeling as seen in section 5), and aggregate study arms or study
cohorts (leveraging SPARQL math constructs such as SUM). Our competency
questions and their SPARQL queries12 can be found on our resources website.
6.2 Cohort Similarity Visualizations
We define cohort similarity as an analytical problem to determine the similarity
or closeness of a patient to a given study population. We currently support de-
termination of cohort similarity by generating visualizations, such as a star plot
(Fig. 4), by overlaying features of patient records against study arm character-
istics. For the purpose of visualization, we select a few sample type-2 diabetes
patient records from the National Health and Nutrition Examination Survey
(NHANES)13. Additionally, we adopt different visual strategies for continuous
and categorical variables. In this paper, on the resources website and through our
faceted browser we only support star plot visualizations for continuous variables,
and we are exploring visualizations such as a pie chart for categorical variables.
12 https://tetherless-world.github.io/study-cohort-ontology/application#
scenarioquery
13 Dataset Information Page. https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/
default.aspx?BeginYear=2015
12 S. Chari et al.
Visualizations are generated on a per study arm, per patient basis, through re-
sults of SPARQL queries triggered to our Table 1 KG. Our visualizations are
built by Python plotting modules such as Seaborn14 and Matplotlib15, and our
visualization code is made available as a resource.
Since our visualizations serve the purpose of being quick assessors, we design
them with reduced complexity. Specifically, we aim for them to (1) contain suffi-
cient detail that is not considered overwhelming and (2) carry information such
as variable ranges and the extent of the patient match, to serve as indicators for
future analysis.
6.3 Faceted Browser
We built a faceted browser tool for medical practitioners by utilizing a Python
model-view-controller framework, Flask16. On the backend (model), we utilized
the RDFLib17 module to trigger SPARQL queries on the ingested ontology and
KG files. Through this tool medical practitioners can interact with our Table
1 KGs, and run cohort similarity analyses on studies of their choice. They can
choose from a list of studies and, subsequently, a faceted view will be rendered for
the study arms of this selected study. As seen in Fig. 4, they can also choose the
variables that they would like to visualize. Hence, our prototype faceted browser
interface serves as a per-study inspection tool and uses NHANES patient records
to illustrate the facets.
7 Results
In the Study Analysis Table 1, shown below, we present a quantitative sum-
marization of the results of each competency question (described in subsection
6.1). Some interesting, medically relevant inferences that we output, and that
are often spoken about in medical literature, include the lack of a representa-
tion of adults above 70,18 and the lack of heterogeneity in treatment effects.19
We were surprised that only 6% of the studies in our evaluation dataset were
conducted on a large-scale, that their study arms were evenly divided, and all
their study subjects were put on the basic, antidiabetes treatment of guanidines.
We also find that the SCO ontology is epistemologically adequate for represent-
ing all Table 1s in our evaluation dataset. We cover 360 (≈ 17 in each study
on average) subject characteristics from 20 cited research studies, and 28 study
arm definitions. The study arm definitions included terms belonging to classes
such as medical interventions, control regimes, and, less commonly occurring,
14 https://seaborn.pydata.org/
15 https://matplotlib.org/
16 http://flask.pocoo.org/
17 https://rdflib.readthedocs.io/en/stable
18 https://www.statnews.com/2019/01/31/nih-rule-make-clinical-research-inclusive/
19 NIH Collaboratory run grand-round presentation: https://www.nihcollaboratory.
org/Pages/Grand-Rounds-02-28-14.aspx
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Table 1. Percentage of studies meeting the competency question criteria for the pop-
ulation analysis scenarios.
Question Percentage Population Analysis Type
Studies with a representation of Male African
American study subjects 75% Study Match
Study Arms with adults below
the age of 70 47.6% Study Limitations
Studies with cohort sizes >1000 and study
arm administered drugs of the guanidines family,
with sizes 1/3rd those of the cohort size
6% Study Quality Evaluation
diseases, dosage, year of follow-ups, and titration targets. We found that 19 co-
hort variables (a term we use to collectively describe interventions and subject
characteristics) commonly occur across studies.
8 Resource Contributions
We expect the following publicly available artifacts, along with the applicable
documentation, to be useful resources for anyone interested in performing anal-
ysis on study populations reported in research studies.
1. Ontologies:
(a) Study Cohort Ontology (SCO)
2. Knowledge Graphs:
(a) Table 1 Knowledge Graph
3. Source Code:
(a) MIREOT Script
(b) Cohort Similarity Visualiza-
tion
4. Data:
(a) NHANES Patient Records
9 Future Work
Having demonstrated our ability to apply semantic techniques to make study
populations visible, we plan to incorporate interdiscplinary methods to improve
on a few aspects of our solution. We have found that there exist variances in Ta-
ble 1 reporting styles ranging from differences in row and column headers, table
formats etc. These variances pose challenges for the scalability and automation
aspects of the KG construction. Furthermore, often some subject characteris-
tics and column headers require a contextual understanding for disambiguation,
that is present in the unstructured body of the study. Hence, we are exploring
a combination of natural language processing and semantic techniques to sup-
port an ontology-driven parsing and clean-up of Table 1 data and to develop a
contextualized and medical standards compliant Table 1 KG. Further, to ensure
longevity and easy reuse of SCO, we plan to develop a set of tools/algorithms
to predict the best-fit position for a new term in our SCO suite of ontologies.
We also plan to expand and refine our set of competency questions, based on
feedback from medical practitioners, and to allow for partial and fuzzy matches
using query relaxation [9] and semantically targeted analytics [14].
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10 Discussion
We have utilized KR techniques, i.e. OWL encodings of SCO and a knowledge
graph of Table 1 content to model and expose descriptions of study populations
in an attempt to make scientific data more accessible. Further, we have uti-
lized our semantic modeling to support analytical use cases to determine study
applicability.Our evaluation dataset currently is solely comprised of type-2 dia-
betes research studies. We have kept our descriptions and examples minimally
domain specific. We believe that our ontology and KG documentation can serve
as resources for researchers interested in the pan-disease analysis of study pop-
ulations.
Our ontology, SCO, is developed using best-practice ontology principles, some of
which are listed at [7]. Specifically, we reuse SIO properties and do not define any
new properties. We reuse classes from a limited yet standard set of biomedical
ontologies in order to increase the interoperability of SCO.
There have been attempts at improving the reporting of Table 1s in the medical
community, such as the Table 1 project [15]. However, they have been confined
to the identification of desirable properties for standardization. Our semantic so-
lution presented in this paper, that at its heart utilizes a KR approach, is a step
towards achieving this standardization. This can be seen in Listing 1.1 where
we have presented an RDF snippet representing fundamental building blocks
of our Table 1 KG, i.e. our modeling of collections, subject characteristics, and
statistical measures. These identified patterns are reused as templates to realize
the association of various variables with study populations reported in Table 1s.
Our Table 1 KGs allows us to address study applicability scenarios motivated
from medical literature and to support visualizations that clearly depict cohort
similarity. By these capabilities, we demonstrate how our solution addresses our
use case of determining study applicability. We believe there is potential for this
work to be reused by researchers performing study population analyses. Also in
this paper we make assumptions on the content a medical practitioner might
want to see, and, from a medical practitioner user survey we are conducting, we
will incorporate feedback on their additional requirements.
Our solution does not address or include support for the modeling of study
eligibility criteria, i.e. inclusion and exclusion criteria. However, we reuse meta-
data expression terms from Dublin Core Terms (DCT) to include a link to reg-
istries such as ClinicalTrials.gov or International Standard Randomised Con-
trolled Trial Number (ISRCTN),20 where the criteria is made available as a part
of the study data. We expect that the SCO vocabulary is sufficient to express
the criteria, but since we are still investigating the merge of the criteria with the
Table 1 content, we defer it to future work.
Finally, all the resources that we listed in section 8, are made publicly available
in a Github repository and the ontology is hosted on Bioportal. SCO is released
under the Apache 2.0 license specification. Our resources will be maintained
periodically by the authors.
20 http://www.isrctn.com/page/about
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11 Conclusion
We have presented a prototype KR system that can be used to model study pop-
ulations, to aid in the assessment of study applicability. Our model is tailored
around use cases aimed at assisting medical practitioners in the treatment of
complex patients and who also often require “efficient-literature searching” [12]
capabilities. We presented a solution to make descriptions of study populations
more accessible for quick decision-making. We believe that the resources we re-
lease, especially SCO, can serve as an extensible schema to represent population
descriptions across diseases. We have demonstrated the adequacy of the ontol-
ogy through a set of what we believe are representative applications supporting
a range of use cases contributed by our medical expert. We plan to continue
our outreach and ontology reuse in additional diverse evidence-based medicine
application settings.
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